当前位置: 首页 >> 检索结果
441. Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma.
The severity of asthma (SOA) score is based on a validated disease-specific questionnaire that addresses frequency of asthma symptoms, use of systemic corticosteroids, use of other asthma medications, and history of hospitalization/intubation for asthma. SOA does not require measurements of pulmonary function. This study compared the ability of SOA to predict clinical outcomes in the EXCELS (Epidemiological Study of Xolair [omalizumab]: Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate to Severe Asthma) patient population vs three other asthma assessment tools. EXCELS is a large, ongoing, observational study of patients with moderate to severe persistent asthma and reactivity to perennial aeroallergens.
442. Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial.
作者: Jean-Christian Borel.;Renaud Tamisier.;Jesus Gonzalez-Bermejo.;Jean-Philippe Baguet.;Denis Monneret.;Nathalie Arnol.;Pascale Roux-Lombard.;Bernard Wuyam.;Patrick Levy.;Jean-Louis Pépin.
来源: Chest. 2012年141卷3期692-702页
Open studies suggest that treatment of obesity hypoventilation syndrome (OHS) by noninvasive ventilation (NIV) restores sleep quality and daytime vigilance and reduces cardiovascular morbidity. However, to our knowledge no randomized controlled trial (RCT) comparing NIV to conservative measures is available in the field. The goal of this study was to assess in patients with OHS, during an RCT, effects of 1-month NIV compared with lifestyle counseling on blood gas measurements, sleep quality, vigilance, and cardiovascular, metabolic, and inflammatory parameters.
443. Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomy.
作者: Kim M Kerr.;William R Auger.;James J Marsh.;Gehan Devendra.;Roger G Spragg.;Nick H Kim.;Richard N Channick.;Stuart W Jamieson.;Michael M Madani.;Gerard R Manecke.;David M Roth.;Gordon P Shragg.;Peter F Fedullo.
来源: Chest. 2012年141卷1期27-35页
We sought to determine the efficacy and safety of perioperative treatment with methylprednisolone on the development of lung injury after pulmonary thromboendarterectomy.
444. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.
作者: Philip M Short.;Peter A Williamson.;Douglas H J Elder.;Samuel I W Lipworth.;Stuart Schembri.;Brian J Lipworth.
来源: Chest. 2012年141卷1期81-86页
Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting β-agonists (LABAs).
445. Does age impact the obese asthma phenotype? Longitudinal asthma control, airway function, and airflow perception among mild persistent asthmatics.
作者: Jason E Lang.;Jobayer Hossain.;Anne E Dixon.;David Shade.;Robert A Wise.;Stephen P Peters.;John J Lima.; .
来源: Chest. 2011年140卷6期1524-1533页
The relationship between obesity and asthma remains inadequately defined. Studies about how obesity affects asthma control and lung function show conflicting results. Additional focus on the effect of age as a modifier may make clearer the interaction between obesity and asthma phenotype. We sought to use a diverse and well-phenotyped cohort of asthmatic patients to determine how age impacts the relationship between obesity and spirometry, peak flow variability, airflow perception, and asthma control.
446. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.
作者: Miguel Ángel Martínez-García.;Juan J Soler-Cataluña.;Pablo Catalán-Serra.;Pilar Román-Sánchez.;Miguel Perpiñá Tordera.
来源: Chest. 2012年141卷2期461-468页
The aim of this study is to evaluate the efficacy and safety of medium-dose formoterol-budesonide combined inhaled treatment in a single inhaler compared with high-dose budesonide treatment in patients with non-cystic fibrosis (non-CF) bronchiectasis.
447. The effect of weight loss and exercise training on flow-mediated dilatation in coronary heart disease: a randomized trial.
作者: Philip A Ades.;Patrick D Savage.;Stefan Lischke.;Michael J Toth.;Jean Harvey-Berino.;Janice Y Bunn.;Maryann Ludlow.;David J Schneider.
来源: Chest. 2011年140卷6期1420-1427页
More than 80% of patients entering cardiac rehabilitation are overweight, with a high prevalence of associated insulin resistance, diabetes, hypertension, hyperlipidemia, and a prothrombotic state. Because each of these characteristics is associated with abnormalities of endothelial-dependent flow-mediated dilatation (FMD), a predictor of long-term prognosis in patients with coronary heart disease (CHD), we assessed the effect of exercise training and weight reduction on FMD in overweight patients with CHD.
448. Systemic vascular dysfunction in patients with chronic mountain sickness.
作者: Stefano F Rimoldi.;Emrush Rexhaj.;Lorenza Pratali.;Damian M Bailey.;Damian Hutter.;Francesco Faita.;Carlos Salinas Salmòn.;Mercedes Villena.;Pascal Nicod.;Yves Allemann.;Urs Scherrer.;Claudio Sartori.
来源: Chest. 2012年141卷1期139-146页
Chronic mountain sickness (CMS) is a major public health problem characterized by exaggerated hypoxemia and erythrocytosis. In more advanced stages, patients with CMS often present with functional and structural changes of the pulmonary circulation, but there is little information on the systemic circulation. In patients with diseases associated with chronic hypoxemia at low altitude, systemic vascular function is altered. We hypothesized that patients with CMS have systemic vascular dysfunction that may predispose them to increased systemic cardiovascular morbidity.
449. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial.
作者: Yvonne Nussbaumer-Ochsner.;Tsogyal D Latshang.;Silvia Ulrich.;Malcolm Kohler.;Robert Thurnheer.;Konrad E Bloch.
来源: Chest. 2012年141卷1期131-138页
Many patients with obstructive sleep apnea syndrome (OSA) are unable or unwilling to use continuous positive airway pressure (CPAP) therapy when traveling to the mountains for work or recreation even though they risk pronounced hypoxemia and exacerbation of sleep apnea. Because the treatment of OSA at altitude has not been established, we tested the hypothesis that acetazolamide improves hypoxemia, sleep, and breathing disturbances in otherwise untreated patients with OSA at altitude.
450. Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke.
作者: Karine L Clearie.;Lorna McKinlay.;Peter A Williamson.;Brian J Lipworth.
来源: Chest. 2012年141卷2期330-338页
Smoking induces airway inflammation and relative resistance to inhaled steroids. The objective of this study was to evaluate the effects on airway hyperresponsiveness of adding salmeterol to fluticasone vs doubling the dose of fluticasone in patients with asthma who smoked and patients with asthma who did not smoke.
451. Noninvasive ventilation in COPD: impact of inspiratory pressure levels on sleep quality.
作者: Michael Dreher.;Emelie Ekkernkamp.;Stephan Walterspacher.;David Walker.;Claudia Schmoor.;Jan H Storre.;Wolfram Windisch.
来源: Chest. 2011年140卷4期939-945页
Although high-intensity noninvasive positive pressure ventilation (HI-NPPV) is superior to low-intensity noninvasive positive pressure ventilation (LI-NPPV) in controlling nocturnal hypoventilation in stable hypercapnic patients with COPD, it produces higher amounts of air leakage, which, in turn, could impair sleep quality. Therefore, the present study assessed the difference in sleep quality during HI-NPPV and LI-NPPV.
452. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
作者: Lewis J Rubin.;David B Badesch.;Thomas R Fleming.;Nazzareno Galiè.;Gerald Simonneau.;Hossein A Ghofrani.;Michael Oakes.;Gary Layton.;Marjana Serdarevic-Pehar.;Vallerie V McLaughlin.;Robyn J Barst.; .
来源: Chest. 2011年140卷5期1274-1283页
The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed.
453. Providing coaching and cotinine results to preteens to reduce their secondhand smoke exposure: a randomized trial.
作者: Melbourne F Hovell.;Dennis R Wahlgren.;Sandy Liles.;Jennifer A Jones.;Suzanne C Hughes.;Georg E Matt.;Ming Ji.;Christina N Lessov-Schlaggar.;Gary E Swan.;Dale Chatfield.;Ding Ding.
来源: Chest. 2011年140卷3期681-689页
Secondhand smoke exposure (SHSe) poses health risks to children living with smokers. Most interventions to protect children from SHSe have coached adult smokers. This trial determined whether coaching and cotinine feedback provided to preteens can reduce their SHSe.
454. Bleeding risk in patients with atrial fibrillation: the AMADEUS study.
作者: Deirdre A Lane.;Pieter W Kamphuisen.;Pascal Minini.;Harry R Büller.;Gregory Y H Lip.
来源: Chest. 2011年140卷1期146-155页
This study aimed to assess the impact of combination antithrombotic therapy on stroke and bleeding risk compared with anticoagulation therapy only in patients with atrial fibrillation (AF).
455. The effect of simulated obstructive apnea and hypopnea on aortic diameter and BP.
作者: Anne-Christin Stöwhas.;Mehdi Namdar.;Patric Biaggi.;Erich W Russi.;Konrad E Bloch.;John R Stradling.;Malcolm Kohler.
来源: Chest. 2011年140卷3期675-680页
Preliminary evidence supports an association between obstructive sleep apnea (OSA) and thoracic aortic dilatation. The mechanisms through which OSA may promote thoracic aortic dilatation are incompletely understood. Therefore, we studied the acute effects of simulated apnea and hypopnea on aortic diameter and BP in humans.
456. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.
作者: Lynette M Brown.;Hubert Chen.;Scott Halpern.;Darren Taichman.;Michael D McGoon.;Harrison W Farber.;Adaani E Frost.;Theodore G Liou.;Michelle Turner.;Kathy Feldkircher.;Dave P Miller.;C Gregory Elliott.
来源: Chest. 2011年140卷1期19-26页
Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder. Despite the emergence of effective therapy, PAH is commonly at an advanced stage when recognized. Factors associated with a prolonged symptomatic period before the recognition of PAH have not been fully evaluated.
457. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
作者: Kenneth R Chapman.;Stephen I Rennard.;Angeli Dogra.;Roger Owen.;Cheryl Lassen.;Benjamin Kramer.; .
来源: Chest. 2011年140卷1期68-75页
Indacaterol is an inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily dosing in patients with COPD.
458. Evaluation of the total face mask for noninvasive ventilation to treat acute respiratory failure.
作者: Aylin Ozsancak.;Samy S Sidhom.;Timothy N Liesching.;William Howard.;Nicholas S Hill.
来源: Chest. 2011年139卷5期1034-1041页
We hypothesized that the total face mask (TFM) would be perceived as more comfortable than a standard oronasal mask (ONM) by patients receiving noninvasive mechanical ventilation (NIV) therapy for acute respiratory failure (ARF) and would be quicker to apply by respiratory therapists.
459. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children.
作者: Ann Chen Wu.;Kelan Tantisira.;Lingling Li.;Brooke Schuemann.;Scott T Weiss.;Anne L Fuhlbrigge.; .
来源: Chest. 2011年140卷1期100-107页
Asthma therapy is typically prescribed and titrated based on patient or parent self-report of symptoms. No longitudinal studies have assessed the relationship between symptoms and severe asthma exacerbations in children. The goal of our study was (1) to assess the association of asthma symptoms with severe asthma exacerbations and (2) to compare predictors of persistent asthma symptoms and predictors of severe asthma exacerbations.
460. Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control.
Patients with mild persistent asthma constitute about 70% of the asthma population; thus, it is important to know which first-line treatment is best for the management of mild asthma. We compared benefits of first-line treatment with ciclesonide and a combination of fluticasone and salmeterol in patients with mild asthma.
|